PDCD1 and neoplasm: Finally, we performed related experiments in the animals and found that HDAC8 inhibitors combined with anti‐PD‐1 therapy markedly inhibited tumor progression (no significant difference in efficacy from the CX4945 plus anti‐PD‐1 therapy group), and application of PC1‐34051 effectively reducing the proportion of CD8+ Tex cells infiltrated within the tumor, as well as enhancing the production of IFN‐γ (Figure 7F,G).